Skip to main content
OpenTrials

Clinical trial condition

Multiple Sclerosis, Relapsing-Remitting

Explore clinical trials studying Multiple Sclerosis, Relapsing-Remitting. Study availability and eligibility vary by location and protocol.

455 public trials 46 recruiting studies
Refine in advanced search Browse all conditions

Multiple Sclerosis, Relapsing-Remitting trial results

Completed

Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy

NCT01498887

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Novartis Investigative Site East Gosford, New South Wales, Australia
  • Novartis Investigative Site Kanwal, New South Wales, Australia
  • Novartis Investigative Site Liverpool, New South Wales, Australia
  • Novartis Investigative Site New Lambton Heights, New South Wales, Australia
View all 47 locations
View Trial Details
Completed

TMP001 in Relapsing-remitting Multiple Sclerosis

NCT02686788

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • UKT, Universitätsklinikum Tübingen Tübingen, Baden-Würtemberg, Germany
  • Goethe-Universität Frankfurt am Main Frankfurt am Main, Hesse, Germany
  • Universitätsklinikum Münster, Klinik für Allgemeine Neurologie Münster, North Rhine-Westphalia, Germany
  • Charite- Universitätsmedizin Berlin (Campus Mitte) NeuroCure Clinical Research Center NCRC AG Klinische Neuroimmunologie Berlin, Germany
View Trial Details
Completed

An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT01838668

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Fakultni nemocnice u sv. Anny v Brne Brno, Czechia
  • Neurospol, s.r.o. Havířov, Czechia
  • Fakultni nemocnice Hradec Kralove Hradec Králové, Czechia
  • Privatni ordinace - neurologie Hradec Králové, Czechia
View all 54 locations
View Trial Details
Completed

A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT00882999

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +11 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Phoenix, Arizona, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tucson, Arizona, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Fullerton, California, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Denver, Colorado, United States
View all 63 locations
View Trial Details
Completed

Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya

NCT02137707

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • University of British Columbia Vancouver, British Columbia, Canada
  • Dalhousie University Multiple Sclerosis Research Unit Halifax, Nova Scotia, Canada
  • Ottawa General Hospital Ottawa, Ontario, Canada
  • Clinique Neuro Rive-Sud Greenfield Park, Quebec, Canada
View Trial Details
Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis

NCT01051349

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Brno, Czechia
  • Research Site Brno, Czechia
  • Research Site Hradec Králové, Czechia
  • Research Site Prague, Czechia
View all 65 locations
View Trial Details

Related conditions